Clearside Biomedical Inc

Clearside Biomedical — Investor Presentation (January 2019)

46 slides from Clearside Biomedical's investor presentation, Jan 7, 2019

  1. Slide 1: Corporate Presentation | January 2019

    Corporate Presentation | January 2019 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”

  3. Slide 3: Proprietary suprachoroidal treatment approach offers access to the back of the eye

    Proprietary suprachoroidal treatment approach offers unprecedented access to the back of the eye Dedicated to developing treatments that restore and preserve vision for people with serious eye diseases A World Without Blindness NDA submitted in 2018

  4. Slide 4: Privileged Organ Requiring Local Therapy

    Privileged Organ Requiring Local Therapy Limitations of Current Therapy: Corticosteroids reach unintended tissues, causing cataracts and glaucoma Gene therapies require precise placement at diseased tissue Multi-kinase inhibitors and complement inhibitors require improved exposure to the choroid ~5

  5. Slide 5: Exclusive and Proprietary Access to the Back of the Eye Through the Suprachoroidal Space

    Exclusive and Proprietary Access to the Back of the Eye Through the Suprachoroidal Space (“SCS”) VS Intravitreal & Periocular Suprachoroidal Fluid flows instantaneously and posteriorly Consistent suprachoroidal injection procedure Fluid with drug is absorbed into the choroid, retinal pigment epithel

  6. Slide 6: Designed to Improve Ocular Distribution of Triamcinolone Acetonide

    Concentration (ng/g) Time, days XIPERE™ The anterior segment is relatively spared following suprachoroidal dosing when compared to intravitreal dosing Designed to Improve Ocular Distribution of Triamcinolone Acetonide (TA) Over 10X the amount of TA remaining in the choroid and RPE following supracho

  7. Slide 7: Focused Pipeline of SCS Treatments For Multiple Blinding Eye Diseases

    INDICATION STUDY DRUG CURRENT STATUS Uveitis (macular edema associated with uveitis) XIPERE (corticosteroid triamcinolone acetonide) DME (diabetic macular edema) XIPERE WET AMD Proprietary Compound(s) DME Proprietary Compound(s) Usher Syndrome Gene Therapy Focused Pipeline of SCS Treatments For Mult

  8. Slide 8: Uveitis: One of the World's Leading Causes of Blindness

    UVEITIS One of the World’s Leading Causes of Blindness

  9. Slide 9: The Opportunity In Treating Macular Edema with Uveitis

    The Opportunity In Treating Macular Edema with Uveitis Primary Need An approved therapy that targets vision impairment due to the underlying macular edema associated with all uveitis The Problem Inflammation creates sight threatening macular edema No approved treatment for macular edema associated w

  10. Slide 10: Current Treatment Paradigm for Uveitis

    Current Treatment Paradigm for Uveitis Note: TA = triamcinolone acetonide Corticosteroids = most common treatment for uveitis complications Periocular (Sub-tenon) 20 mg TA Sustained release dexamethasone implant (Ozurdex®) Intravitreal 4 mg TA Topical steroid for anterior uveitis 350,000 patients US

  11. Slide 11: Non-Infectious Uveitis Market is Sizeable and Growing

    Non-Infectious Uveitis (“NIU”) Market is Sizeable and Growing Anticipated to Grow at 9% YoY US NIU Market Forecast (in millions) Market basket Includes eye drops, ocular injections, corticosteroid implants, systemic corticosteroids, immunomodulatory therapies, and biologics Global uveitis market exp

  12. Slide 12: 2018 Share of NIU Patients with Macular Edema

    2018 Share of NIU Patients with Macular Edema Market Research1: 2 Published Literature: Between 1/3 to 1/2 of NIU Patients Develop Macular Edema * Ophthalmologists with uveitis / retina fellowship who see ≥ 5 patients with macular edema secondary to NIU Sources: 1) Target Ophthalmologist ATU, May 20

  13. Slide 13: Status of Current Therapy in Macular Edema Associated with Uveitis

    Status of Current Therapy in Macular Edema Associated with Uveitis The POINT Study1,3 1. Thorne, 2018; study was conducted and funded by the NEI 2. 2nd injections were based on macular edema criteria, either because of not improving or worsening edema 3. Clearside does not make any comparative claim

  14. Slide 14: PEACHTREE Pivotal Phase 3 Clinical Trial Testing XIPERE

    PEACHTREE Pivotal Phase 3 Clinical Trial Testing XIPERE in CME Involved Uveitis 3:2 randomization of XIPERE vs. sham injection; 160 subjects total Primary endpoint at 6 months; superiority of best corrected visual acuity outcome from treatment CONTROL Week-2 Day 0 Day 0 Week 4 Week 8 Week 12 Week 16

  15. Slide 15: PEACHTREE Met Its Primary Endpoint

    46.9% (n=45) 15.6% (n=10) % subjects gaining ≥15 ETDRS letters in BCVA from baseline PEACHTREE Met Its Primary Endpoint ETDRS BCVA Proportion of subjects in each arm gaining ≥ 15 ETDRS letters in BCVA from baseline at Week 24 p<0.001 N=96 N=64

  16. Slide 16: PEACHTREE Met Its Secondary Endpoint

    PEACHTREE Met Its Secondary Endpoint Mean Change from Baseline in CST at Week 24 in Microns Mean change from baseline at week 24 in central retinal thickness (microns) 480.9 µm: active arm; 525.4 µm: control arm p<0.001 Baseline retinal thickness (microns) N=96 N=64 Intention-to-treat (ITT) Source:

  17. Slide 17: Vision Gained Rapidly and Sustained Through Week 24

    Vision Gained Rapidly and Sustained Through Week 24 Mean Change in BCVA in ETDRS Letters by Visit Baseline ETDRS letters read 54.7: active arm; 53.5: control arm Mean change at each visit from baseline in BCVA in ETDRS letters read p<0.001 Source: Table 14.2.3.1

  18. Slide 18: Subject Rescue: Kaplan-Meier

    Subject Rescue: Kaplan-Meier Proportion of Subjects Not Rescued Time to Rescue (days) Active Control + Censored Over 85% of subjects in the Active arm did not require rescue therapy, compared to 28% of subjects in the Control arm

  19. Slide 19: Approx. 50% of Active Subjects Could Read 20/40

    Starting at week 8, approx. 50% of the Active subjects could read 70 or more ETDRS letters (20/40) This improvement was sustained through the 24 weeks of the trial % Subjects Reading 20/40 or Better Legal Driving Vision in Most States Percent Subjects Baseline Week 24 Baseline Week 24

  20. Slide 20: XIPERE Resolves Inflammation in 2 of 3 Subjects in PEACHTREE

    % subjects with scores of zero at week 24 *Standardization of Uveitis Nomenclature XIPERE Resolves Inflammation in 2 of 3 Subjects in PEACHTREE Resolution of each of these three signs of inflammation on the SUN* scales is clinically and statistically significant In subjects with scores of 2 or great

  21. Slide 21: Visual Improvement Across Four Anatomic Subtypes of Uveitis

    Subjects From Each of the Four Anatomic Subtypes of Uveitis Treated with XIPERE Achieved Significant Visual Improvement Intention-to-treat population, last observation carried forward. Intermediate p=0.032 Visit Week p=0.016 Visit Week Anterior Mean change in BCVA (ETDRS letters read) p=0.005 Poster

  22. Slide 22: Safety: Elevated IOP

    Safety: Elevated IOP “Elevated IOP” includes (a) increased IOP, (b) ocular hypertension, and (c) glaucoma AE = adverse event; IOP, intraocular pressure. ** intravitreal OZURDEX® (dexamethasone intravitreal implant) and subtenon and intravitreal triamcinolone acetonide N=11/96 N=10/64 Percent Subject

  23. Slide 23: Safety: Cataracts in XIPERE and Control Arms

    Safety: Cataracts in XIPERE and Control Arms Percentage of cataract AEs Mar-2018 | NIU program | P3, PEACHTREE, trial | Topline data % Cataract AEs in Each Arm No cataract surgeries in this trial

  24. Slide 24: Specialists Perceive High Unmet Need Among Current Therapies

    Specialists Perceive High Unmet Need Among Current Therapies, with Greatest Concern Over Elevated IOP Perceived Unmet Need for treating ME Secondary to NIU Top Unmet Needs in Treating ME Secondary to NIU No unmet need Very high unmet need Source: Target Ophthalmologist ATU, May 2018

  25. Slide 25: ~70% of Specialists React Favorably to CLS-TA Profile

    When Introduced to CLS-TA Profile, ~70% of Specialists React Favorably and Are Interested in Using Overall Reaction to CLS-TA Interest in Using CLS-TA Not at all favorable Very favorable Not at all interested Very interested “When you’ve got a drug that is that same you’ve been using all along but y

  26. Slide 26: DME: Potential Path Forward for XIPERE as a Monotherapy

    DME Potential Path Forward for XIPERE as a Monotherapy

  27. Slide 27: The Opportunity In Treating DME

    The Opportunity In Treating DME Primary Need The Problem DME course and response to anti-VEGF injection is largely variable 40% and 55% of patients have continued macular edema in years 2 and 3, respectively, even after monthly intravitreal anti-VEGF injections Need for ongoing monthly intravitreal

  28. Slide 28: Current Treatment Paradigm for DME

    Current Treatment Paradigm for DME Eylea, Lucentis, and off-label Avastin® Sustained release steroid (Ozurdex®) Intravitreal Triamcinolone Acetonide 8.3 M patients Diabetic Retinopathy patients in U.S. 2nd Line treatment 1.1 M patients Diabetic Macular Edema (DME) patients 1 2 3 1st Line treatment

  29. Slide 29: TYBEE Design for Phase 2 DME Clinical Trial

    TYBEE Design for Phase 2 DME Clinical Trial Any additional treatment based on as needed criteria at Week 16 and Week 20 will be intravitreal Eylea Evaluate at 6 months Day 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Enrollment Day 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Control arm: Intr

  30. Slide 30: Quarterly Treatments with XIPERE and Anti-VEGF Showed Similar Outcomes

    Mean change from baseline in BCVA by visit Error bars are 90% confidence intervals of the means Baseline BCVA in ETDRS letters: 58: control arm; 57: active arm Quarterly Treatments with XIPERE and Anti-VEGF Showed Similar Outcomes to Anti-VEGF Given Monthly XIPERE appears to be able to extend visual

  31. Slide 31: Lesson 1: CST Persisted Through Week 24

    Lesson 1: Central Subfield Thickness (CST) Persisted Through Week 24 Mean Change from Baseline in CST by Visit Mean change from baseline in CST (microns) Wk04 Wk08 Wk12 Wk16 Wk24 Wk20 Day 0 Each arm shows a statistically significant improvement in CST from baseline at week 24 (*p<0.001)

  32. Slide 32: Lesson 2: Resolution of CST By Visit

    Lesson 2: Resolution* of CST By Visit *Defined as CST <300 microns | CST: central subfield thickness A significantly greater percentage of subjects in the Combination arm showed resolution* in their CST at the week 4 visit (p<0.01) compared to those in the Control arm The greater resolution in CST a

  33. Slide 33: Lesson 3: Equivalent Vision with Fewer Treatments

    Lesson 3: Combination Arm Achieved Equivalent Vision with Fewer Treatments Number of additional Eylea Injections in the PRN stage (1) ~50% fewer treatments through week 12 ~57% fewer treatments in the PRN period (p=0.03) (1) p=0.03

  34. Slide 34: Path Forward in DME

    Path Forward in DME Current anti-VEGFs require retreatment every 4 to 8 weeks Subjects gained approximately 10 letters and were maintained for 12 weeks with XIPERE + intravitreal Eylea in TYBEE XIPERE has the potential to maintain visual gains on a quarterly dosing regimen and could address treatmen

  35. Slide 35: RVO

    RVO

  36. Slide 36: TANZANITE Phase 2 Trial: XIPERE with Intravitreal Eylea for RVO

    1 Based on post-hoc analysis Number of patients who received additional Intravitreal Eylea Intent-to-treat (ITT) population: N = 46 (23:23) Intent-to-treat (ITT) population: N = 46 (23:23) Additional Intravitreal Eylea injections p=0.013 p=0.0031 XIPERE + Intravitreal Eylea Intravitreal Eylea TANZAN

  37. Slide 37: TANZANITE: Improved Visual Acuity Over Time

    TANZANITE: Improved Visual Acuity Over Time XIPERE + Intravitreal Eylea resulted in more improved visual acuity at months 1, 2, 3 vs. intravitreal Eylea alone BCVA letter read: change from baseline M1 Control M1 Combination M2 Control M2 Combination M3 Control M3 Combination ITT population N = 46 (2

  38. Slide 38: TANZANITE Safety Summary

    TANZANITE Safety Summary All subjects completed the TANZANITE trial There were no serious adverse events AEs ≥5% in any arm were: conjunctival haemorrhage (8.7%; 4.3%); IOP increased (0%; 8.7%); eye pain (8.7%; 30.4%), ocular hypertension (0%; 8.7%); XIPERE and intravitreal Eylea used together in th

  39. Slide 39: SAPPHIRE Phase 3 Study Design

    SAPPHIRE Control arm: Intravitreal Eylea; Q4Wk Combination arm: XIPERE + Intravitreal Eylea; Q12Wk Day 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Week ww Week xx Week yy Week zz 2 Month primary efficacy endpoint Enrollment Day 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Week ww Week xx Week

  40. Slide 40: SAPPHIRE 8-Week Topline Results

    Primary endpoint was to determine proportion of subjects in each arm gaining ≥ 15 ETDRS letters from baseline at eight weeks In SAPPHIRE, control and combination were similar and did not meet its primary endpoint ~50% of subjects gained 15 ETDRS letters from baseline in both arms There was not a sta

  41. Slide 41: A World Without Blindness: In Summary

    A WORLD WITHOUT BLINDNESS In Summary

  42. Slide 42: Opportunity is Well Protected

    14 U.S. Patents Total 3 Apparatus using loss-of-resistance technology 1 Administration of any anti-inflammatory drug to the suprachoroidal space by microinjection 1 Method of treating macular edema 2 Methods using loss-of-resistance technology Apparatus having / methods using an adjustable puncture

  43. Slide 43: Accomplished Leadership Team With Deep Ophthalmic Experience

    Accomplished Leadership Team With Deep Ophthalmic Experience Experience Years Daniel White President, CEO and Director GSK, Stiefel, CIBA Vision, Alimera 25 Thomas Ciulla, M.D., MBA Chief Medical Officer Spark Therapeutics, Indiana University School of Medicine 27 Charles Deignan Chief Financial Off

  44. Slide 44: Multiple Potential Value Inflection Points

    Multiple Potential Value Inflection Points Uveitis FDA acceptance of NDA PDUFA response U.S. Launch EMA application Other Pipeline Additional data from 6 month Sapphire results DME program update Additional non clinical results from 2 preclinical gene therapy programs Additional preclinical data on

  45. Slide 45: Investment Summary

    Investment Summary Lead product candidate, XIPERE, for the treatment of macular edema associated with uveitis Pivotal Phase 3 PEACHTREE trial success NDA submitted in Q4-2018 If approved, XIPERE would be the first therapy with this indication Building commercial readiness for potential U.S. launch i

  46. Slide 46: Thank You!

    THANK YOU! We see a world without blindness; relentlessly pursuing transformative, elegant, precise solutions to restore and preserve vision.

Clearside Biomedical — Investor Presentation (January 2019) on 6ix